Mega Genomics Limited provided group earnings guidance for the year ended 31 December 2022. The board of directors of the Company informed the shareholders of the Company and potential investors of the Company that, based on the preliminary assessment on the Group's unaudited consolidated management accounts for the year ended 31 December 2022 and the information currently available to the Board, the Group is expected to record a net loss attributable to owners of the parent for the year ended 31 December 2022 of approximately RMB 13 million to RMB 22 million (the net profit attributable to owners of the parent for the year ended 31 December 2021: RMB 79 million).